SCHEMBL201434

SCHEMBL201434

Clc1ccc2nc(CBr)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.47
HDAC1 Q13547 2/20 0.46
HDAC2 Q92769 2/20 0.46
PDE10A Q9Y233 1/20 0.43
HTR3A P46098 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
FAAH O00519 1/20 0.41
BACE1 P56817 2/20 0.40
CYP2A6 P11509 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
NR4A2 P43354 1/20 0.36
TEC P42680 1/20 0.36
F7 P08709 1/20 0.35
F3 P13726 1/20 0.35
DYRK1A Q13627 1/20 0.35
PIK3CG P48736 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29518426 0.86 CCR1 (0.48) CCR1PDE10AHTR3ACYP2A6HRH3
SCHEMBL203068 0.86 CCR1 (0.48) CCR1PDE10AHTR3ACYP2A6HRH3
SCHEMBL27529644 0.85 PDE10A (0.47) HDAC1HDAC2PDE10AHTR3AHRH4
SCHEMBL2412433 0.82 HDAC1 (0.47) HDAC1HDAC2PDE10AHTR3AHRH4
SCHEMBL7808149 0.81 HDAC1 (0.49) CCR1HDAC1HDAC2PDE10AHTR3A
SCHEMBL5103462 0.81 HDAC1 (0.46) HDAC1HDAC2PDE10AHTR3AHRH4
SCHEMBL9022559 0.81 PDE10A (0.46) HDAC1HDAC2PDE10AHTR3AHRH4
SCHEMBL9203570 0.78 CCR1 (0.48) CCR1PDE10AHRH3DYRK1AALDH1A1
SCHEMBL11872340 0.78 CCR1 (0.48) CCR1HDAC1HDAC2BACE1TEC
SCHEMBL2322461 0.78 BACE1 (0.55) CCR1HDAC1HDAC2BACE1CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-20230047589-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2023-02-16 US disclosed
US-11230542-B2 Inhibitors of integrated stress response pathway Praxis Biotech LLC (US) 2022-01-25 US disclosed
CN-111757739-A Integrated stress pathway inhibitors 普拉西斯生物技术有限责任公司 2020-10-09 CN disclosed
US-20190177310-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY Praxis Biotech LLC 2019-06-13 US disclosed
US-9682972-B2 1,2,5-substituted benzimidazoles as flap modulators JANSSEN PHARMACEUTICA NV (BE) 2017-06-20 US disclosed
US-9682971-B2 1,2,5-Substituted benzimidazoles as flap modulators JANSSEN PHARMACEUTICA NV (BE) 2017-06-20 US disclosed
US-20160108028-A1 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-04-21 US disclosed
US-9265770-B2 1,2,5-substituted benzimidazoles as FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2016-02-23 US disclosed
US-20160046600-A1 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS CHAI WENYING (US) 2016-02-18 US disclosed
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC 2004-09-09 US disclosed
US-6649657-B2 Administering amide to treat osteoporosis PFIZER INC. 2003-11-18 US disclosed
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLEY Q (US) 2003-06-05 US disclosed
US-6492412-B2 ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF SULFONAMIDE OR ALKANOY OR AMIDE DERIVATIVE CONTAINING HETERO OR AROMATIC RINGS TO TREAT OSTEOPOROSIS, OSTEOTOMY, CHILDHOOD IDIOPATHIC BOEN LOSS ETC. PFIZER, INC. 2002-12-10 US disclosed
US-20020016368-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLY O (US) 2002-02-07 US disclosed
US-6344485-B1 Method for treating glaucoma PFIZER INC. 2002-02-05 US disclosed
US-6288120-B1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. 2001-09-11 US disclosed
EP-1000619-A2 Method for treating glaucoma Pfizer Products Inc. (US) 2000-05-17 EP disclosed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 EP disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 CCR1 1684/4885HDAC1 3574/4885HDAC2 3551/4885
US-20020016368-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 CCR1 1684/4885HDAC1 3574/4885HDAC2 3551/4885
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 CCR1 1684/4885HDAC1 3574/4885HDAC2 3551/4885
US-11230542-B2 Inhibitors of integrated stress response pathway ATF4, DDIT3, ATF1 CCR1 4448/4885HDAC1 937/4885HDAC2 805/4885
US-20160046600-A1 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS FEN1, FOXM1, CYP3A5 CCR1 311/4885HDAC1 159/4885HDAC2 695/4885
US-20230047589-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 CCR1 4448/4885HDAC1 937/4885HDAC2 805/4885
US-20190177310-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 CCR1 4448/4885HDAC1 937/4885HDAC2 805/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 CCR1 286/4885HDAC1 801/4885HDAC2 1831/4885
US-20160108028-A1 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS FEN1, FOXM1, CYP3A5 CCR1 311/4885HDAC1 159/4885HDAC2 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.